|
1
|
Sherman SL, Allen EG, Bean LH and Freeman
SB: Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev.
13:221–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kwon JY, Park IY, Kwon SM, Kim CJ and Shin
JC: The quadruple test for Down syndrome screening in pregnant
women of advanced maternal age. Arch Gynecol Obstet. 285:629–633.
2012. View Article : Google Scholar
|
|
3
|
Kolialexi A, Tsangaris GT, Papantoniou N,
et al: Application of proteomics for the identification of
differentially expressed protein markers for Down syndrome in
maternal plasma. Prenat Diagn. 28:691–698. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang L, Dai Y, Qi S, Sun B, Wen J, Zhang L
and Tu Z: Comparative proteome analysis of peripheral blood
mononuclear cells in systemic lupus erythematosus with iTRAQ
quantitative proteomics. Rheumatol Int. 32:585–593. 2012.
View Article : Google Scholar
|
|
5
|
Garbis SD, Tyritzis SI, Roumeliotis T, et
al: Search for potential markers for prostate cancer diagnosis,
prognosis and treatment in clinical tissue specimens using
amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid
chromatography and tandem mass spectrometry. J Proteome Res.
7:3146–3158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bouchal P, Roumeliotis T, Hrstka R,
Nenutil R, Vojtesek B and Garbis SD: Biomarker discovery in
low-grade breast cancer using isobaric stable isotope tags and
two-dimensional liquid chromatography-tandem mass spectrometry
(iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J
Proteome Res. 8:362–373. 2009. View Article : Google Scholar
|
|
7
|
Sun C, Song C, Ma Z, et al: Periostin
identified as a potential biomarker of prostate cancer by
iTRAQ-proteomics analysis of prostate biopsy. Proteome Science.
9:222011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kolla V, Jenö P, Moes S, Tercanli S,
Lapaire O, Choolani M and Hahn S: Quantitative proteomics analysis
of maternal plasma in Down syndrome pregnancies using isobaric
tagging reagent (iTRAQ). J Biomed Biotechnol. 2010:9520472010.
View Article : Google Scholar
|
|
9
|
Sui W, Tang D, Zou G, Chen J, Ou M, Zhang
Y and Dai Y: Differential proteomic analysis of renal tissue in
lupus nephritis using iTRAQ reagent technology. Rheumatol.
32:3537–3543. 2012. View Article : Google Scholar
|
|
10
|
Abdi F, Quinn JF, Jankovic J, et al:
Detection of biomarkers with a multiplex quantitative proteomic
platform in cerebrospinal fluid of patients with neurodegenerative
disorders. J Alzheimers Dis. 9:293–348. 2006.PubMed/NCBI
|
|
11
|
Shilov IV, Seymour SL, Patel AA, et al:
The Paragon Algorithm, a next generation search engine that uses
sequence temperature values and feature probabilities to identify
peptides from tandem mass spectra. Mol Cell Proteomics.
6:1638–1655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hyman BT, West HL, Rebeck GW, et al:
Quantitative analysis of senile plaques in Alzheimer disease:
Observation of log-normal size distribution and molecular
epidemiology of differences associated with apolipoprotein E
genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA.
92:3586–3590. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Strohmeyer R, Shen Y and Rogers J:
Detection of complement alternative pathway mRNA and proteins in
the Alzheimer’s disease brain. Brain Res Mol Brain Res. 81:7–18.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu B, Zhang B, Wang J, Wang QW, Huang RP,
Yang YQ and Shao SH: Preliminary proteomic-based identification of
a novel protein for Down’s syndrome in maternal serum. Exp Biol Med
(Maywood). 237:530–539. 2012. View Article : Google Scholar
|
|
15
|
Kossmann T, Stahel PF, Morganti-Kossmann
MC, Jones JL and Barnum SR: Elevated levels of the complement
components C3 and factor B in ventricular cerebrospinal fluid of
patients with traumatic brain injury. J Neuroimmunol. 73:63–69.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Head E, Azizeh BY, Lott IT, Tenner AJ,
Cotman CW and Cribbs DH: Complement association with neurons and
beta-amyloid deposition in the brains of aged individuals with Down
syndrome. Neurobiol Dis. 8:252–265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stoltzner SE, Grenfell TJ, Mori C,
Wisniewski KE, Wisniewski TM, Selkoe DJ and Lemere CA: Temporal
accrual of complement proteins in amyloid plaques in Down’s
syndrome with Alzheimer’s disease. Am J Pathol. 156:489–499. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pepys MB, Baltz ML, de Beer FC, et al:
Biology of serum amyloid P component. Ann NY Acad Sci. 389:286–298.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perlmutter LS, Barrón E, Myers M, Saperia
D and Chui HC: Localization of amyloid P component in human brain:
vascular staining patterns and association with Alzheimer’s
disease. J Comp Neurol. 352:92–105. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rowe IF, Jennson O, Lewis P, Candy J,
Tennent GA and Pepys MB: Immunohistochemical demonstration of
amyloid P component in cerebro-vascular amyloidosis. Neuropathol
Appl Neurobiol. 10:53–61. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tokairin T, Nishikawa Y, Watanabe H, et
al: Osteopontin expression in the liver with severe perisinusoidal
fibrosis: Autopsy case of Down syndrome with transient
myeloproliferative disorder. Pathol Int. 58:64–68. 2008. View Article : Google Scholar
|
|
22
|
Belgrader P, Dey R and Berezney R:
Molecular cloning of matrin 3. A 125-kilodalton protein of the
nuclear matrix contains an extensive acidic domain. J Biol Chem.
266:9893–9899. 1991.PubMed/NCBI
|
|
23
|
Hisada-Ishii S, Ebihara M, Kobayashi N and
Kitagawa Y: Bipartite nuclear localization signal of matrin 3 is
essential for vertebrate cells. Biochem Biophys Res Commun.
354:72–76. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Senderek J, Garvey SM, Krieger M, et al:
Autosomal-dominant distal myopathy associated with a recurrent
missense mutation in the gene encoding the nuclear matrix protein,
matrin 3. Am J Hum Genet. 84:511–518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeitz MJ, Malyavantham KS, Seifert B and
Berezney R: Matrin 3: chromosomal distribution and protein
interactions. J Cell Biochem. 108:125–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Salton M, Lerenthal Y, Wang SY, Chen DJ
and Shiloh Y: Involvement of Matrin 3 and SFPQ/NONO in the DNA
damage response. Cell Cycle. 9:1568–1576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Przygodzka P, Boncela J and Cierniewski
CS: Matrin 3 as a key regulator of endothelial cell survival. Exp
Cell Res. 317:802–811. 2011. View Article : Google Scholar
|
|
28
|
Bernert G1, Fountoulakis M and Lubec G:
Manifold decreased protein levels of matrin 3, reduced motor
protein HMP and hlark in fetal Down’s syndrome brain. Proteomics.
2:1752–1757. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Labudova O, Krapfenbauer K, Moenkemann H,
Rink H, Kitzmüller E, Cairns N and Lubec G: Decreased transcription
factor junD in brains of patients with Down syndrome. Neurosci
Lett. 252:159–162. 1998. View Article : Google Scholar : PubMed/NCBI
|
